Clients benefit from these alternative techniques where established bioanalysis methods are not suitable for the sample or drug. For example, some compounds cannot be detected easily by established detection methods or where biological components in the clinical sample cause interferences during the analysis.
Biotechnology Program Manager, Ashleigh Wake (Intertek Life Sciences), said: “Our clients require alternative options to address the challenges they face during preclinical and clinical development programs for complex novel drugs. At Intertek, we are experts at adapting non-traditional techniques for bioanalytical applications.” Ashleigh Wake will present a review of alternative bioanalytical methods with case studies on Thursday 20th November 2014 during EBF.
Intertek’s bioanalytical laboratories in San Diego and Eldorado Hills (USA) and Manchester (UK) are Good Laboratory Practice (GLP) compliant and offer method development, validation and bioanalysis to support pre-clinical and clinical studies. Core strengths include LC-MS/MS and immunochemistry and alongside this Intertek has the expertise to develop and apply nonstandard bioanalytical methods which are compliant with GLP or Good Clinical Practice (GCP) where appropriate.
The EBF Symposium (Barcelona, Spain, November 19th – 21st 2014) is a forum for the bioanalytical community, to discuss current industry challenges such as regulatory developments or new techniques.
To request a copy of the presentation please email: firstname.lastname@example.org
Or to sign up for the webinar on this topic visit; http://www.intertek.com/pharmaceutical/bioanalysis/webinars/
Dr Lorna Kettle
Intertek Pharmaceutical Services
Tel.:+44 161 721 1476